SLF CIL36590 Phase IIb COPD
Latest Information Update: 21 Jul 2016
At a glance
- Drugs SLFCIL 36590 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chiesi Farmaceutici
- 21 Jul 2016 New trial record